What is BRC-001 used for?

BRC-001 is indicated for Relapsed or refractory multiple myeloma.

BRC-001 is developed by City of Hope Medical Center.

What are the side effects of BRC-001?

Common side effects include Fatigue, Nausea, Diarrhea.

Last reviewed 2026-04-23 · How we verify

BRC-001

City of Hope Medical Center · Phase 2 active Small molecule

BRC-001 is a small molecule targeting the CD47/SIRPα axis.

BRC-001 is a small molecule targeting the CD47/SIRPα axis. Used for Relapsed or refractory multiple myeloma.

At a glance

Generic name	BRC-001
Also known as	Cannabidiol, CBD, CBD Oil
Sponsor	City of Hope Medical Center
Drug class	CD47/SIRPα axis inhibitor
Target	CD47
Modality	Small molecule
Therapeutic area	Oncology
Phase	Phase 2

Mechanism of action

BRC-001 works by blocking the interaction between CD47 and SIRPα on the surface of cancer cells, which can lead to enhanced phagocytosis and reduced tumor growth.

Approved indications

Relapsed or refractory multiple myeloma

Common side effects

Fatigue
Nausea
Diarrhea

Key clinical trials

High Cannabidiol Plant Extract (BRC-001) to Improve Aromatase Inhibitor-Induced Arthralgia in Women With Breast Cancer (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

BRC-001 CI brief — competitive landscape report
BRC-001 updates RSS · CI watch RSS
City of Hope Medical Center portfolio CI